A5011970860- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Synthesis and Biological Activity
- CAR-T cell therapy research
- Cancer Mechanisms and Therapy
- Renal cell carcinoma treatment
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Insect Resistance and Genetics
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Hematopoietic Stem Cell Transplantation
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
University of Kentucky
2022-2025
Good Samaritan Medical Center
2025
Central Michigan University
2020-2022
University of Arizona
2018-2019
Allegheny Health Network
2019
Milligan College
2019
Objectives: Non-Hodgkin lymphomas (NHL) are a diverse group of lymphoproliferative malignancies, often more unpredictable than Hodgkin lymphomas, with higher likelihood extranodal spread. NHL’s resistance to standard chemotherapy has increased, leading growing interest in personalized treatments like chimeric antigen receptor T-cell therapies (CAR-TCT). Methodology: A literature search was conducted across PubMed, ScienceDirect, Google Scholar, and the Cochrane Library for studies on CAR-TCT...
559 Background: Renal cell carcinoma (RCC) with brain metastases presents a clinical challenge. Management remains unclear, as systemic therapy data are limited and many trials exclude patients active metastases. Current treatment primarily involves CNS-targeted radiation (e.g., stereotactic radiosurgery whole-brain therapy), while therapies like tyrosine kinase inhibitors (TKIs) immune checkpoint (ICIs) underexplored. This meta-analysis evaluates the efficacy of treatments whether these...
Objectives: Acute lymphoblastic leukemia (ALL) is a common hematological malignancy that occurs due to blockage of B-lymphocyte maturation at an early stage development and differentiation. The Food Drug Administration approved blinotumomab manage relapsed/refractory ALL (R/R ALL). This review aimed determine the comparative efficacy blinatumomab in treating R/R ALL. Methods: Two reviewers searched 3 electronic databases, PubMed, ScienceDirect, CENTRAL, for all relevant articles published...
Studies have reported second malignancies occurring in patients with chronic myeloid leukemia (CML) or lymphoid (CLL). We discuss the case of a 77-year-old man diagnosed CLL who later developed CML. The was managed surveillance after diagnosis for 3 years and treated ibrutinib venetoclax. While on treatment venetoclax 4 months, patient had worsening leukocytosis shown via peripheral flow cytometry fluorescence situ hybridization, presence lineage cells positive BCR-ABL complete disappearance...
5-fluorouracil (5FU) and capecitabine are fluoropyrimidine anti-neoplastic drugs commonly used in the treatment of different types cancer. Hereditary dihydropyrimdine deaminase (DPD), thymidylate synthase mutations drug overdose may lead to life-threatening toxicities. Uridine triacetate (UTA) is an emergency for overdoses early onset, severe or toxicities from fluoropyrimidines. It approved use adults children within 96 h last administration. We present case a 64-year-old male treated with...
Immune checkpoint inhibitors are rapidly becoming popular therapeutic options for patients suffering from a number of malignancies. Atezolizumab is programmed cell death ligand-1 inhibitor, and binding to this ligand decreases the ability tumor cells evade immune system, resulting in self-tolerance. While inhibition these molecules leads increased T-cell destruction cells, it also may lead autoimmune healthy cells. Neurotoxicity rare complication inhibitor therapy, facial palsy as...
"CLO24-080: Association Between Primary Tumor Size and Prognosis in De Novo Metastatic Renal Cell Carcinoma Patients Who Underwent First Line Immunotherapy-Based Therapy: Real World Data Analysis" published on 05 Apr 2024 by National Comprehensive Cancer Network.
403 Background: The CARMENA study found no survival benefit from cytoreductive nephrectomy (CN) in poor-risk metastatic renal cell cancer (mRCC) patients treated with first line Sunitinib. Although retrospective studies have reported benefits CN following immunotherapy (IO)-based therapy, the timing remains unclear. We aimed to investigate ideal of IO using National Cancer Database. Methods: 783 de novo mRCC were diagnosed between 2016 and 2020 who received upfront systemic therapy underwent...
"CLO24-077: Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma the Era Immunotherapy: An Analysis National Cancer Database (NCDB)" published on 05 Apr 2024 by Comprehensive Network.
e15629 Background: Results from multiple trials lead to modern management for locally advanced rectal cancer, with total neoadjuvant therapy (TNT) followed by surgery. However, the best sequence of different treatment modalities is unclear. Methods: We used National Cancer Database (NCDB) identify patients adenocarcinoma. divided into categories based on timing chemo and radiation relative chi-square Wilcoxon rank test unadjusted comparison. To compare efficacy initial chemotherapy...